🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05832723
Recruiting Observational

A Real-world Study of 650nm Low-intensity Single-wavelength Red Light for Children and Adolescents

NCT05832723 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tongren Hospital
Phase
Observational
Started
2023-04-15
Last updated
2024-10-08

Condition(s) studied

Myopia

Investigational drug(s) / intervention(s)

650 nm low-level red-light

650 nm low-level red-light: Typically, children who uses the 650 nm low-level red-light will be recruited into this study. The use of any other myopia intervention is not restricted except for low concentrations of atropine. Because atropine will cause pupils dilated, the amount of light entering the eye can not be controlled, and red-light is a laser, to be safe, we need to take certain consideration of the amount of light-entering. Participants receive the 650 nm low-level red-light intervention not because they are enrolled in a study, they would receive the intervention in the same manner and intensity if they were not enrolled in the study.

Study summary

To evaluate the efficacy and safety of 650nm low-level red-light irradiation for myopia control and prevention in children under less restrictive conditions than randomized controlled trials. Participants included children(aged 7 to 18 years, spherical equivalent error of 0.5D or below) who are already myopic at recruitment, and those who are of Emmetropia or low hyperopia.

Eligibility

Sex
ALL
Min age
7 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Children aged 7 to 18 years 2. The cycloplegic spherical equivalent error (SER) is +0.5D or less in both eyes 3. Astigmatism of 2.5 D or less (≤2.5D) 4. Willing to participate in the study and sign the informed consent form Exclusion Criteria: 1. Including but not limited to the following eye diseases: strabismus, amblyopia, ocular tumors, glaucoma/macular disease and other fundus diseases (including heredity), keratitis, eye trauma, uveitis 2. Including but not limited to the following systemic diseases: epilepsy, tumor, heart disease, asthma, systemic immune diseases, infectious diseases 3. Mental diseases 4. Similar interventions have been used in the past year 5. Allergic to cycloplegic agents or to red light 6. The 650nm red light intervention was not suitable for the condition evaluated by the researchers 7. are currently using atropine or similar drugs, or have stopped using them for less than 1 month

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Red light Beijing Beijing Municipality Recruiting

More Beijing Tongren Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05832723 on ClinicalTrials.gov ↗ ← All trials in China